Drug news
CHMP recommends Senshio as a treatment for Vulvar and Vaginal Atrophy- Shionogi
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Senshio (ospemifene), 60 mg, Film-coated tablet, from Shionogi, intended for the treatment of moderate to severe symptomatic Vulvar and Vaginal Atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
Ospemifene was FDA approved in 2013 as Osphena.